Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management

European Journal of Cancer, Supplement

Volumn 5, Issue 7, 2007, Pages 12-19

  Négrier, Sylvie ^a   Ravaud, Alain ^b,c  

^a CENTRE LÉON BÉRARD   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Adverse events; Renal cell carcinoma; Tyrosine kinase receptors

Indexed keywords

ACEBUTOLOL; ALPHA INTERFERON; AMLODIPINE; ANTIDIARRHEAL AGENT; ANTIHYPERTENSIVE AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CORTICOSTEROID; CYTOKINE; ENALAPRIL; FELODIPINE; FOSINOPRIL; IRBESARTAN; LABETALOL; LISINOPRIL; LOPERAMIDE; LOSARTAN; METOPROLOL; NIFEDIPINE; PERINDOPRIL; PROTEIN TYROSINE KINASE INHIBITOR; QUINAPRIL; RAMIPRIL; RETINOL; SUNITINIB; TELMISARTAN; UNINDEXED DRUG; UREA; VALSARTAN;

ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; BRAIN METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DEPIGMENTATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; EPISTAXIS; FATIGUE; FOLLICULITIS; HAND FOOT SYNDROME; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; KIDNEY CARCINOMA; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PANCREATITIS; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; RASH; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 35548970733     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(07)70110-6     Document Type: Article

References (16)

1. Motzer R., Michaelson M., Redman B., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 1 (2006) 16-24
2. Motzer R., Rini B., Bukowski R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 21 (2006) 2516-2524
3. Motzer R., Hutson T., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 2 (2007) 115-124
4. Gore M. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded open access trial with subpopulation analysis. J Clin Oncol 25 18S (2007) 5010
5. SUTENT, Summary of Product Characteristics. January 2007. Pfizer Inc 2007.
6. Houk B., Bello C., Michaelson M., et al. Exposure- response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach. J Clin Oncol 25 18S (2007) 5027
7. SUTENT (sunitinib malate) prescribing information (2006), Pfizer Inc, New York, NY
8. Sane D., Anton L., and Brosnihan K. Angiogenic growth factors and hypertension. Angiogenesis 7 3 (2004) 193-201
9. Struijker Boudier H., le Noble J., Messing M., et al. The microcirculation and hypertension. J Hypertens Suppl 10 7 (1992) S147-S156
10. Veronese M., Mosenkis A., Flaherty K., et al. Mechanisms of hypertension associated with BAY 43- 9006. J Clin Oncol 24 9 (2006) 1363-1369
11. Kollmannsberger C., Soulieres D., Wong R., et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1 2Suppl (2007) S41-S54
12. Robert C., Soria J., Spatz A., et al. Cutaneous side- effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6 7 (2005) 491-500
13. Webster-Gandy J., How C., and Harrold K. Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 11 3 (2007) 238-246
14. Rini B., Tamaskar I., Shaheen P., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 1 (2007) 81-83
15. Feldman D., Martorella A., Robbins R., et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 99 12 (2007) 974-975
16. de Castro Jr. G., and Awada A. Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). Curr Opin Oncol 18 4 (2006) 307-315